Gastrointestinal bleedings during therapy with new oral anticoagulants are rarely reported

Morten Bay-Nielsen¹, Jens Peter Kampmann² & Thue Bisgaard¹

ABSTRACT
INTRODUCTION: Post-marketing surveillance of drugs relies on spontaneous reporting of adverse drug events to the Health and Medicines Authority. A number of new oral anticoagulants (NOAC) have recently been marketed in Denmark. The purpose of this study was to evaluate the reporting of serious adverse drug events in patients treated with a NOAC and admitted for gastrointestinal bleeding.

MATERIAL AND METHODS: This study is based on an electronic free text search in patient records and a search in the electronic medication records of all patients admitted to the Department of Gastroenterology, Surgical Section, Hvidovre Hospital, during a one-year-period. Patients in treatment with NOAC and admitted for gastrointestinal bleeding were identified. Relevant patients were cross-checked for a reported adverse drug event in the Danish Health and Medicines Authority’s database on adverse medical events.

RESULTS: A total of 20 patients were acutely admitted for gastrointestinal bleeding while in treatment with a NOAC, an adverse medical event was reported for one of these patients (5%; 95% confidence interval: 0-25%).

CONCLUSION: Serious adverse events in patients treated with NOAC are underreported which questions the current effectiveness of post-marketing surveillance of adverse drug effects.

FUNDING: not relevant.
TRIAL REGISTRATION: The study was registered with clinicaltrials.gov (NCT02107651).

Post-marketing surveillance in Denmark is primarily based on mandatory reporting of adverse drug events. Under Danish pharmaceutical legislation, all adverse effects of treatment with drugs are to be reported to the Danish Health and Medicines Authority if the drug is newly marketed (defined as occurring within two years of marketing) or if the event is serious (defined as fatal or causing hospital admission) regardless of time in relation to marketing.

Adverse effects of medical treatment are probably underreported. Underreporting of serious adverse effects in Denmark has not recently been evaluated systematically. Since 2007, several new oral anticoagulants (NOAC), including dabigatran etilexate (Pradaxa) and rivaroxaban (Xarelto), have been registered for use in Denmark.

The purpose of this study was to evaluate if the routine post-marketing surveillance system captures serious adverse drug events in patients treated with NOAC. Thus, we systematically registered reports of adverse drug effects recorded by the Danish Health and Medicines Authority in patients admitted for gastrointestinal bleeding while undergoing NOAC treatment.

METHODS AND MATERIAL
The study was a consecutive case series based on retrospective analysis of patient records. Patients in treatment with NOAC at the time of admission were identified among all patients admitted to the Department of Gastroenterology, Surgical Section, Hvidovre Hospital, Denmark, during a one-year-period from 1 January 2012 to 31 December 312012, by a): a search algorithm in the free-text medical patient records for all occurrences of the text-strings: “dabigat”, “pradax”, “xarel”, “rivarox” or b): use of NOAC documented in the electronic medication record. Acute admission for treatment of gastrointestinal bleeding (index admission) was identified by manual review of the files of the patients identified by the above described search strategy. Information regarding type of bleeding, morbidity and dosage of NOAC was extracted. Estimated glomerular filtration rate (eGFR) was calculated on the basis of the plasma creatinine level at the time of admission [1]. Patients in treatment with NOAC and admitted for gastrointestinal bleeding were cross-checked for occurrence of a reported adverse event in the Danish Health and Medicines Authority’s database on adverse medical events more than a year after the date of the index admission. The surgical department (a non-private university clinic with unrestricted referral) receives all patients admitted for acute gastrointestinal bleeding within a catchment area counting 512,000. The department has 9,000 acute admissions per year of which approximately 30% are for evaluation of upper or lower gastrointestinal bleeding. The study was reported to the Danish Data Protection Agency (reference number 01675-HVH-2012-010). In pursuance of Danish research guidelines for retrospective studies and quality assur-
## TABLE 1

Details on gastrointestinal bleeding episode, co-morbidity and new oral anticoagulant medication. A total of 20 patients admitted for gastrointestinal bleeding and in new oral anticoagulant treatment at time of admission.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Gender/age, yrs</th>
<th>Type of bleeding</th>
<th>Haemoglobin at time of admission, mmol/l</th>
<th>Plasma-creatininine concentration at time of admission, µmol/l</th>
<th>Endoscopy/finding at endoscopy</th>
<th>Co-morbidity</th>
<th>NOAC medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M/66</td>
<td>Haematochezia</td>
<td>5.8</td>
<td>52</td>
<td>Gastroscopy/no specific pathology found</td>
<td>AF, type 2 DM</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>2</td>
<td>M/69</td>
<td>Haematemesis and melena</td>
<td>2.7</td>
<td>184</td>
<td>Gastroscopy/no specific pathology found</td>
<td>COPD, AF, CHF, type 2 DM, lung cancer</td>
<td>Pra 150 mg × 2</td>
</tr>
<tr>
<td>3</td>
<td>M/83</td>
<td>Haematochezia</td>
<td>7.9</td>
<td>88</td>
<td>Sigmoideoscopy/ no specific pathology found</td>
<td>Asthma, AF, depression</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>4a</td>
<td>M/76</td>
<td>Severe anaemia</td>
<td>4.3</td>
<td>168</td>
<td>Colonoscopy/ angiodysplasia</td>
<td>AF, CHF</td>
<td>Pra 150 mg × 2</td>
</tr>
<tr>
<td>5</td>
<td>F/87</td>
<td>Melena</td>
<td>4.4</td>
<td>123</td>
<td>No/n.a.</td>
<td>AF, AH, previous admissions for nosebleeds</td>
<td>Pra 75 mg × 2</td>
</tr>
<tr>
<td>6</td>
<td>F/80</td>
<td>Severe anaemia</td>
<td>4.2</td>
<td>134</td>
<td>Gastroscopy/gastric ulcer, non-bleeding</td>
<td>AF, type 2 DM</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>7</td>
<td>F/88</td>
<td>Haematochezia</td>
<td>6.7</td>
<td>65</td>
<td>Sigmoideoscopy + gastroscopy/no specific pathology found</td>
<td>AF, CHF, hypothyreosis</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>8</td>
<td>M/76</td>
<td>Haematochezia</td>
<td>8.8</td>
<td>121</td>
<td>Sigmoideoscopy/ bleeding haemorrhoids</td>
<td>AF, sinus node dysfunction</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>9</td>
<td>M/70</td>
<td>Haematochezia</td>
<td>5.9</td>
<td>101</td>
<td>Gastroscopy/oesophagitis</td>
<td>AH, type 2 DM</td>
<td>Pra (dosage unknown)</td>
</tr>
<tr>
<td>10</td>
<td>M/70</td>
<td>Haematochezia and melena</td>
<td>6.6</td>
<td>92</td>
<td>Gastroscopy/bleeding prepyloric ulcer</td>
<td>AF, previous gastro-duodenal ulcer</td>
<td>Pra 150 mg × 2</td>
</tr>
<tr>
<td>11</td>
<td>K/90</td>
<td>Haematochezia</td>
<td>7.3</td>
<td>109</td>
<td>No/n.a.</td>
<td>AF, anal prolapse, INR 1.3</td>
<td>Pra 110 mg × 2  (for 2 days VKA discontinued 2 days pre admission)</td>
</tr>
<tr>
<td>12</td>
<td>M/67</td>
<td>Haematemesis and melena</td>
<td>4.1</td>
<td>143</td>
<td>Gastroscopy/gastric ulcer, non-bleeding</td>
<td>AF, AH, microscopic haematuria</td>
<td>Pra 150 × 2</td>
</tr>
<tr>
<td>13</td>
<td>K/72</td>
<td>Haematochezia</td>
<td>6.9</td>
<td>506</td>
<td>Gastroscopy/no specific pathology found</td>
<td>AH, type 2 DM, sequelae from previous cerebral apoplexy</td>
<td>Pra 150 mg × 2,</td>
</tr>
<tr>
<td>14</td>
<td>K/83</td>
<td>Haematochezia</td>
<td>7.4</td>
<td>42</td>
<td>No/n.a.</td>
<td>AF, AH, rectal cancer, sequelae from previous cerebral apoplexy</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>15</td>
<td>K/91</td>
<td>Haematochezia</td>
<td>8.2</td>
<td>113</td>
<td>No/n.a.</td>
<td>AF, AH, chronic leg ulcers</td>
<td>Pra 75 mg × 2</td>
</tr>
<tr>
<td>16</td>
<td>K/82</td>
<td>Melena</td>
<td>3.8</td>
<td>185</td>
<td>Gastroscopy/gastritis</td>
<td>AF, type 2 DM, sequelae from previous cerebral apoplexy, 3rd-degree AV block</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>17</td>
<td>M/75</td>
<td>Haematochezia</td>
<td>8.7</td>
<td>124</td>
<td>No/n.a.</td>
<td>Lung cancer, haemorrhoids</td>
<td>Pra 110 mg × 1</td>
</tr>
<tr>
<td>18</td>
<td>M/83</td>
<td>Haematemesis</td>
<td>5.8</td>
<td>164</td>
<td>Gastroscopy/ oesophagitis</td>
<td>AF, AH, aortic stenosis, COPD, CHF</td>
<td>Pra 110 mg × 2</td>
</tr>
<tr>
<td>19</td>
<td>K/89</td>
<td>Haematochezia</td>
<td>6.5</td>
<td>80</td>
<td>Gastroscopy/no specific pathology found</td>
<td>Sequelae from previous cerebral apoplexy, previous episode of deep vein thrombosis and pulmonary embolus, INR 1.3</td>
<td>Xar 20 mg × 1 (for 3 days - VKA discontinued 3 days pre admission)</td>
</tr>
<tr>
<td>20</td>
<td>M/81</td>
<td>Haematemesis</td>
<td>5.6</td>
<td>197</td>
<td>Gastroscopy/gastric ulcer, bleeding</td>
<td>AH, bleeding episode post-operatively after knee alloplasty</td>
<td>Xar 20 mg × 1</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; AH = arterial hypertension; AV = atrioventricular; CHF = chronic heart failure; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; F = female; INR = international normalized ratio; M = male; n.a. = not available; NOAC = new oral anticoagulant; Pra = Pradaxa (dabigatran etilexate); VKA = vitamin K-antagonist; Xar = Xarelto (rivaroxaban).

a) Patient with occurrence of a reported adverse event in the Danish Health and Medicines Authority’s database.
ance, approval from an ethics committee was not re-
quired.

Descriptive statistics are presented using fre-
quencies, percentages, and 95% confidence intervals
(CIs) when appropriate.

**Trial registration:** The study was registered with clinicaltrials.gov (NCT02107651).

**RESULTS**

Only one patient (5%; 95% CI: 0-24%) was recorded by
the Danish Health and Medicines Authority as having an
adverse drug event associated with NOAC treatment.

During the one-year study period, 65 patients in
NOAC treatment were admitted to the surgical depart-
ment. Among these patients, 20 were admitted for
acute gastrointestinal bleeding. Details on gastrointes-
tinal bleeding episode, co-morbidity and NOAC medica-
tion are shown in Table 1. The median haemoglobin
level at the time of admission was 6.1 mg/l (interquartile
range: 5.2-7.4 mg/l), 12 patients (60%; 95% CI: 36-81%) received one or more SAG-M transfusions and 12 pa-
tients (60%; 95% CI: 36-81%) underwent emergency
endoscopy, of which only one was therapeutic and ten
were diagnostic. The median age was 80.5 years, the
median eGFR was 30 ml/min (interquartile range: 40-20
ml/min), 55% were males, the median length of stay was
four days (interquartile range: 1-11 days), and no pa-
tients died during admission. Most patients (n = 11)
were admitted for lower gastrointestinal bleeding,
whereas seven patients were admitted for upper gastro-
intestinal bleeding and two patients were admitted with
severe anaemia (haemoglobin level < 4.5 mmol/l) and
clinical suspicion of gastrointestinal bleeding.

**DISCUSSION**

We found a low reporting rate for serious adverse drug
effects in patients treated with NOAC.

The adverse effect profile for NOAC therapies in-
cludes risk of bleeding episodes comparable to the pro-
file for conventional vitamin K antagonists (VKAs).
Although reported to have an overall lower risk of bleed-
ing than VKAs, a higher risk of specific gastrointestinal
bleeding is found in patients treated with NOAC [2].
Furthermore, the patients in this material are old and a
high proportion have renal impairment, factors associ-
ated with an increased risk of adverse effects in patients
treated with NOAC [3]. A causal relation between con-
current NOAC treatment and admission for a bleeding
episode is thus likely. By statutory provision, the report-
ing of such adverse drug events is mandatory. Our find-
ing that most (95%) of the serious adverse drug effects
in patients treated with NOAC go unreported questions
the efficiency of the current post-marketing surveillance
in Denmark. This potentially has implications for the
regulatory agencies’ ability to improve patient safety.

Identification of potential patients by use of text
mining is conceptually simple when based on a combina-
tion of highly selective text terms and manual review of
cases and can be used for many purposes. In contrast,
using text mining to exclude irrelevant cases is a com-
plex process, as exclusion has to be based on context
and semantics, although comprehensive algorithms to
automatically detect and classify possible adverse drug
events have previously been described [4].

The reason for the observed underreporting of ser-
ious adverse drug events remains unknown. It is prob-
ably related to the large number of physicians involved
in the treatment of acutely admitted patients, all with a
focus on diagnosis and treatment, and without a clear
responsibility for the reporting of a specific adverse drug
effect. In this context, a newly organised system for re-
porting adverse drug effects introduced in the Copen-
hagen Region (the “Adverse Drug Effect Manager”) fa-
cilitates the reporting process with the aim of lowering
the threshold for and the workload involved in the re-
porting. This increases the spontaneous reporting of ad-
verse drug effects [5].

In the US, a perceived high frequency of serious and
fatal episodes of bleeding in patients treated with dabig-
arat etilexate has led to specific analysis of available
data in administrative and insurance claims data bases.
Based on this analysis, it was concluded that the high
number of reported bleeding episodes were due to non-
pharmacological issues, including the increased focus on
a new drug, known as the Weber-effect or “stimulated
reporting” [6]. Using readily available information in
clinical information systems could be an efficient way to
systematically monitor post-marketing safety for newly
introduced drugs in Denmark, and it would supplement
an apparently flawed system of unsystematic reporting
of adverse drug effects. However, the complexity
needed to establish such a central monitoring system
could be significant.

The present study does not quantify the risk of gas-
trointestinal bleeding in relation to NOAC treatment as

Post-marketing surveil-
ance of drugs relies on
spontaneous reporting of
adverse drug events to
the Health and Medicines
Authority.
the number of patients in the catchment area who undergo NOAC treatment is unknown. The study is limited by only focusing on reporting of adverse drug effects related to treatment with NOAC in patients admitted to a single department. However, it is very likely that similar results would be found in relation to other types of anticoagulants, including VKAs, in relation to other types of substances and in other settings.

CONCLUSION

By systematic use of electronic medical record data, we found that severe adverse drug effects in patients treated with NOAC are underreported. This indicates that there may be a need for a more systematic approach to post-marketing surveillance of adverse drug effects.

CORRESPONDENCE: Morten Bay-Nielsen, Gastroenheden, Kirurgisk Sektion, Hvidovre Hospital, Kettegård Allé 30, 2650 Hvidovre, Denmark. E-mail: mortenbay@dadlnet.dk.

ACCEPTED: 10 September 2014.

CONFLICTS OF INTEREST: Disclosure forms provided by the authors are available with the full text of this article at www.danmedj.dk.

LITERATURE